Work

Prognostic Impact of Checkpoint Inhibitor Pneumonitis: Results from a Multicenter Prospective Observational Study (CS-Lung004)

Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening adverse event caused by anti-programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies. However, paradoxical findings have been reported regarding the association between overall survival (OS) and CIP. This study aimed to prospectively evaluate the relationship between the 2-year OS and CIP in patients receiving first-line treatment, including anti-PD-1/PD-L1 antibody therapy, using 3-month and 1-year landmark analyses. METHODS: A multicenter prospective observational study was conducted between December 2021 and November 2023 to evaluate the prognostic impact of CIP, based on timing and severity, in patients with non-small cell lung cancer (NSCLC). RESULTS: Although no significant difference in OS was observed between patients with and without CIP developed within 2 years or 1 year, the 3-month landmark analysis showed that patients who developed CIP within 3 months had significantly shorter OS than those who did not (median OS from the 3-months landmark: 11.1 months with CIP versus not reached without CIP; log-rank p = 0.011). In multivariate Cox regression analyses, using patients without CIP as the reference group, CIP within 3 months was significantly associated with impaired overall survival (any-grade CIP: hazard ratio [HR] = 2.22, 95% confidence interval [CI]=1.21-4.09; Grade 3-5 CIP: HR=3.37, 95% CI=1.57-7.23). CONCLUSION: This was the first prospective study to demonstrate the prognostic value of CIP. CIP within 3 months after the initiation of first-line treatment, including anti-PD-1/PD-L1 antibody, especially Grade 3-5 CIP, was associated with shorter OS in patients with NSCLC.
Source: Lung
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,290
OpenAlex ID: W7236569364
FWCI:
Cites: 20
Cited by:
Related to: 10